TVTX · Travere Therapeutics, Inc.

This FDA approval represents a major commercial and clinical inflection point for Travere: FILSPARI is now the first and only therapy approved for FSGS without nephrotic syndrome — a distinct, previously untreated patient population aligned with KDIGO guidelines. The expansion doubles FILSPARI’s labeled indications, adding FSGS to its existing IgA nephropathy (IgAN) approval, thereby broadening its addressable U.S. market to over 30,000 patients. Clinical validation comes from the pivotal Phase 3 DUPLEX Study — the largest interventional FSGS trial to date — which met its primary endpoint with statistically significant improvements in both proteinuria reduction (48% vs. 27% for irbesartan, p=0.0075) and eGFR preservation (1.1 mL/min/1.73 m² treatment difference) specifically in the non-nephrotic subgroup. Critically, the study design explicitly defined nephrotic syndrome using objective, clinically accepted criteria (proteinuria >3.5 g/24h or UPCR >2.0 g/g, albumin <3.0 g/dL, edema), ensuring the population is well-characterized and commercially targetable. The safety profile remained consistent with prior studies and comparable to irbesartan, supporting rapid adoption. As FILSPARI transitions from a single-indication asset to a foundational therapy across two rare glomerular diseases, its revenue potential, payer coverage pathways, and competitive positioning are materially enhanced — particularly given the absence of alternative FDA-approved treatments for FSGS without nephrotic syndrome.